MPM Bioimpact LLC Has $16.45 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

MPM Bioimpact LLC lifted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 18.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 391,018 shares of the biopharmaceutical company's stock after buying an additional 61,285 shares during the period. Ultragenyx Pharmaceutical makes up 2.3% of MPM Bioimpact LLC's portfolio, making the stock its 17th biggest position. MPM Bioimpact LLC owned 0.42% of Ultragenyx Pharmaceutical worth $16,450,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of RARE. Van ECK Associates Corp lifted its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after acquiring an additional 294 shares in the last quarter. BOKF NA raised its holdings in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 493 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Ultragenyx Pharmaceutical by 2.4% during the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock worth $1,011,000 after acquiring an additional 568 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on RARE. Morgan Stanley increased their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. JPMorgan Chase & Co. increased their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler decreased their target price on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Monday, March 17th. Finally, HC Wainwright reissued a "buy" rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $90.93.

Ultragenyx Pharmaceutical Stock Up 0.6%

NASDAQ:RARE traded up $0.22 during trading hours on Monday, hitting $35.83. 278,033 shares of the stock were exchanged, compared to its average volume of 824,059. The company's 50 day moving average is $36.39 and its two-hundred day moving average is $41.64. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The company has a market capitalization of $3.39 billion, a P/E ratio of -5.67 and a beta of 0.34.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The firm had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the company posted ($2.03) EPS. The firm's quarterly revenue was up 28.0% compared to the same quarter last year. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the company's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider John Richard Pinion sold 14,439 shares of the company's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $607,881.90. Following the completion of the transaction, the insider now directly owns 107,766 shares of the company's stock, valued at approximately $4,536,948.60. The trade was a 11.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 125,405 shares of company stock valued at $5,285,169. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.